CA-ASM-GLOBAL
23.11.2022 02:58:42 CET | Business Wire | Press release
ASM Global, the world’s leading venue management company and producer of live experiences, has made history with the spectacular firework-laden inauguration ceremony of the 950,000-square-foot Exhibition World Bahrain—the largest exhibition centre in the Middle East.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005879/en/
Image courtesy of ASM Global
The Kingdom’s Exhibition World is one of the most contemporary such venues in the world. Its launch is a milestone in the Kingdom’s economic development and is expected to play a key role in advancing the economic competitiveness and positioning of Bahrain as a major global destination for regional and international conventions.
The venue joins ASM Global’s portfolio of more than 350 venues around the world and kicks off the company’s post-pandemic convention growth initiative.
ASM Global’s President and CEO Ron Bension said, “This moment is the culmination of our plan developed during the pandemic leveraging our belief that this part of the world would be the quickest to not only return to normal but move quickly to dramatically increase its convention and exhibition market share.
“We’re also looking forward to leveraging the widest network in the world within the MICE industry to create unique experiences built on years of expertise.”
The opening extravaganza was attended on behalf of His Majesty King Hamad bin Isa Al Khalifa, by His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister of Bahrain.
HRH Prince Salman bin Hamad highlighted the importance of competitiveness as a fundamental element of the kingdom’s economy, which has bolstered investments, promoted economic progress and created quality opportunities for citizens. He also noted that tourism remains a leading economic sector, adding that the sector's growth has been a key driver of the kingdom’s comprehensive development, led by His Majesty the King.
During the ceremony, Bahrain Tourism Minister H.E. Fatima Al Sairafi noted the kingdom’s longstanding history in being a destination linking the east and west for trade, which has furthered its position as a global tourist destination. She added that the inauguration of the venue reflects the kingdom’s commitment to expanding cross-sector development in line with Bahrain's sustainable development goals.
Exhibition World Bahrain is unique for its adaptable and flexible design, featuring 10 halls with a combined total of 95,000 sqm. The spectacular Grand Hall has a capacity of 4,000 seated guests and is supported by 94 meeting rooms as well as 25 F&B and retail outlets throughout the exhibition concourse. The centre’s spacious design enables it to host a number of events simultaneously, making it an attractive location for local, regional and international exhibitions, conventions, galas, weddings, concerts, sports, and live entertainment events.
Exhibition World Bahrain is owned by the Bahrain Tourism and Exhibitions Authority (BTEA), which plans to utilize ASM Global’s wider network within the MICE industry to create unique experiences built on years of expertise.
ASM Global APAC and Gulf Region Chairman and Chief Executive Harvey Lister AM congratulated BTEA on the inauguration of Exhibition World Bahrain, one of the Middle East’s largest exhibition and convention centres.
“ASM Global is proud to be working in partnership with BTEA helping to ensure Bahrain will be at the forefront of attracting tourism investment, international conventions and exhibitions and world-class live events to the Gulf region,” Lister said. “This iconic landmark venue will further position Bahrain as an international destination, helping to drive diversification of growth, benefiting the local economy and further enhancing the kingdom’s global standing.”
Exhibition World Bahrain General Manager Dr Debbie Kristiansen said she was extremely proud of her dedicated and committed team and their passion and determination to “give back” to the beautiful country of Bahrain, helping to create long-term legacies for the future. Dr Kristiansen highlighted the importance of mentoring and building the talent and skillset of young Bahrainis describing it as a “privilege.”
Following the grand opening, Exhibition World Bahrain immediately opened to the public with three concurrent events expected to see well over 100,000 visitors over the span of five days: Jewellery Arabia, the premier jewellery and watch show celebrating its 30th edition; Scent Arabia’s first-ever exhibition; and Cityscape, the region’s largest real estate summit and exhibition.
ASM Global’s network hosts 20,000 events and welcomes 165 million guests every year. Other flagship exhibition and convention centres in its portfolio include McCormick Place in Chicago; Moscone Center in San Francisco; ICC Sydney; Shenzhen World in China; and P&J Live in Aberdeen, U.K.
About ASM Global
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centres, and performing arts venues. Follow us on Facebook, Instagram, Twitter and LinkedIn. asmglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom